Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 3, 2015, Pages 410-416

  Kröpelin, Tobias F ^a   De Zeeuw, Dick ^a   Andress, Dennis L ^b   Bijlsma, Maarten J ^c   Persson, Frederik ^d   Parving, Hans Henrik ^e,f   Heerspink, Hiddo J Lambers ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ABBVIE INC   (United States)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d STENO DIABETES CENTER   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALISKIREN; ATRASENTAN; CREATININE; LOSARTAN; PARICALCITOL; PLACEBO; AMIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BONE DENSITY CONSERVATION AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ERGOCALCIFEROL; FUMARIC ACID DERIVATIVE; PYRROLIDINE DERIVATIVE;

ADULT; ALBUMINURIA; ARTICLE; DIABETIC NEPHROPATHY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MEASUREMENT PRECISION; MICTURITION; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; THERAPY EFFECT; AGED; AMBULATORY CARE; DIABETIC NEPHROPATHIES; METHODOLOGY; MIDDLE AGED; STATISTICS; STATISTICS AND NUMERICAL DATA; URINE; URINE SAMPLING;

AGED; ALBUMINURIA; AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BONE DENSITY CONSERVATION AGENTS; DIABETIC NEPHROPATHIES; ENDOTHELIN RECEPTOR ANTAGONISTS; ERGOCALCIFEROLS; FEMALE; FUMARATES; HUMANS; LOSARTAN; MALE; MIDDLE AGED; OFFICE VISITS; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; STATISTICS AS TOPIC; URINE SPECIMEN COLLECTION;

EID: 84924351689     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07780814     Document Type: Article

References (12)

1. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D: Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 376: 1543–1551, 2010.
2. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433–2446, 2008.
3. Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P; GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators: Effects of different ACE inhibitor combinations on albuminuria: Results of the GUARD study. Kidney Int 73: 1303–1309, 2008.
4. Witte EC, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort R: Firstmorning voids are more reliable than spot urine samples to assess microalbuminuria. J AmSoc Nephrol 20: 436–443, 2009.
5. de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa-Rotter R, Kohan D, Lambers Heerspink HJ, Makino H, Perkovic V, Pritchett Y, Remuzzi G, Tobe SW, Toto R, Viberti G, Parving HH: The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 25: 1083–1093, 2014.
6. Hanley JA, Negassa A, Edwardes MD, Forrester JE: Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 157: 364–375, 2003.
7. Smulders YM, Slaats EH, Rakic M, Smulders FT, Stehouwer CD, Silberbusch J: Short-term variability and sampling distribution of various parameters of urinary albumin excretion in patients with non-insulin-dependent diabetes mellitus. J Lab Clin Med 132: 39–46, 1998.
8. American Diabetes Association: Standards of medical care in diabetes—2014. Diabetes Care 37[Suppl 1]: S14–S80, 2014.
9. Chronic Kidney Disease Working Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3: 1–150, 2013.
10. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort RT; PREVEND Study Group: Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 168: 897–905, 2008.
11. Lambers Heerspink HJ, Gansevoort RT, Brenner BM, Cooper ME, Parving HH, Shahinfar S, de Zeeuw D: Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol 21: 1355–1360, 2010.
12. Lambers Heerspink HJ, Nauta FL, van der Zee CP, Brinkman JW, Gansevoort RT, de Zeeuw D, Bakker SJ: Alkalinization of urine samples preserves albumin concentrations during prolonged frozen storage in patients with diabetes mellitus. DiabetMed 26: 556–559, 2009.